26.11 USD
▼-2.85-9.84%
盘后 30.50 0.00%
2026-09-15
市值
$518.79M
市盈率
—
EPS
-0.00
股息率
—
52 周区间
20.23 – 39.71
成交量
588.84K
Beta
1.13
目标价
52.00
52W 低 20.2352W 高 39.71
价格走势
公司简介
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next g...